Safety and immunogenicity of direct venus...

In the News

IHI names winners of research, innovation fund

[Right-Left] Getrud, Beatrice, Theckla, and Tutu.Ifakara Health Institute (IHI) has named recipients of the 2017/18 Director’s Research and Innovation Fund. This is an internal funding mechanism aimed to support specific …

Study reports boys, girls start working in the mines at 7

(Dar es Salaam, May 8, 2018). New findings of a formative study by Ifaraha Health Institute (IHI) and partners which focused on children in mining show that child miners, both …

Recent Projects

Development of a new tool for malaria mosquito surveillance to improve vector control

Malaria transmission is influenced not only by vector abundance, but as well by demographic traits such as vector species and age structure, as these influence the intensity by which the …

Demonstrating complete disruption of residual malaria transmission by eliminating Anopheles funestus mosquitoes from rural Tanzanian villages

In rural south-eastern Tanzania, where malaria prevalence has reduced by >60% since 2000, low-to-moderate transmission still persists despite very high coverage with long-lasting insecticidal bednets. Like in most residual transmission …

Clinical Trial to Evaluate the Safety and Immunogenicity in Age De-Escalation of Direct Venous Inoculation of a Plasmodium falciparum Sporozoite Vaccine in Tanzanian Adults, Children, and Infants

A single center, double blind, randomized, normal saline placebo-controlled trial of PfSPZ vaccine OR PfSPZ challenge, administered by Direct Venous Inoculation (DVI). The trial is aimed at evaluating safety, tolerability and vaccine-induced humoral and cellular immune responses of PfSPZ Vaccine in healthy male and female Tanzanian adults, adolescents, children, and infants (from 6 months old) who receive doses of 1.8×10⁶, 9.0×10⁵,  4.5×10⁵ or 2.7×10⁵ PfSPZ of PfSPZ and to assess efficacy in adults three weeks and twenty four weeks following immunization using Controlled Human Malaria Infection (CHMI). A total of 105 subjects will be enrolled at the trial completion

Lead Scientists:

Said Jongo

Salim Abdulla

Partners

No items found

Funders

The government of Equitorial Guinea, Marathon Oil, Noble Energy and AMPCO

Projects Location

A PIXELBASE DESIGN
© Ifakara Health Institute (IHI), 2016